MetaCure

About:

MetaCure develops implantable devices for the treatment of Type II (adult) diabetes.

Top Investors: Morningside Group

Description:

MetaCure develops implantable devices for the treatment of Type II (adult) diabetes. Their key product, Tantalus, delivers electrical pulses to the stomach when a person eats, causing gastric contractions.

Total Funding Amount:

$20M

Estimated Revenue Range:

$1M to $10M

Headquarters Location:

Kfar Saba, HaMerkaz, Israel

Founded Date:

2003-01-01

Contact Email:

contact(AT)metacure.com

Founders:

Shlomo Ben-Haim, Shlomo Haim

Number of Employees:

11-50

Last Funding Date:

2009-05-10

IPO Status:

Private

Industries: